PRL-8-53 is a synthetic substituted benzoic acid ester derivative engineered for in vitro neurochemical research, synaptic transmission assays, and monoaminergic signaling modeling. PRL-8-53 functions as a cholinergic and dopaminergic potentiator, augmenting post-synaptic responsiveness to acetylcholine and modulating dopamine turnover in neuronal cell preparations without provoking non-vesicular monoamine dumping. Modern Aminos supplies PRL-8-53 as an analytical-grade reference standard strictly for laboratory research, receptor binding kinetics, and neurochemical pathway screening.
$38.00
In stock
PRL-8-53 (known chemically as methyl 3-(2-(benzyl(methyl)amino)ethyl)benzoate hydrochloride) is a synthetic substituted benzoic acid ester derivative developed to evaluate synaptic receptor kinetics and neurotransmitter transmission in laboratory models. Structurally characterized by a methyl benzoate backbone linked via an ethylene bridge to a benzyl-methylamine group, PRL-8-53 serves as a specialized biochemical probe for investigating cholinergic and catecholaminergic signaling cascades.
Operating across central nervous system tissue models, PRL-8-53 acts as a cholinergic facilitator and dopamine-potentiating agent. In neurocellular preparations, it amplifies post-synaptic responsiveness to acetylcholine without functioning as an acetylcholinesterase inhibitor or directly binding orthosteric muscarinic receptor sites. Concurrently, it modulates dopaminergic neurotransmission and striatal dopamine turnover in cellular assays without triggering non-vesicular monoamine efflux or receptor down-regulation.
Furthermore, preclinical evaluations demonstrate that PRL-8-53 exhibits modulatory interactions with central serotonergic pathways, altering 5-HT signaling thresholds in isolated tissue preparations. This multi-target receptor interaction makes PRL-8-53 a valuable reference compound for mapping cross-talk between cholinergic, dopaminergic, and serotonergic networks in vitro.
Batch-verified for high analytical purity and mass accuracy at Modern Aminos, PRL-8-53 is supplied in pre-measured 10MG dry-fill solid capsules (60 units per bottle). Researchers evaluating synaptic transmission kinetics, synaptosomal dynamics, and monoaminergic pathways study PRL-8-53 alongside complementary reference standards available on the site, such as Noopept, Phenylpiracetam Hydrazide, Bromantane, and Sunifiram.
| Compound Name | PRL-8-53 |
|---|---|
| Format / Quantity | 10MG Dry-Fill Solid Capsules (60 Units per Bottle) |
| Biological Target | Central Cholinergic Transmission & Dopaminergic Synaptosomes (In Vitro) |
| Chemical Classification | Substituted Benzoic Acid Ester / Tertiary Aminoethyl Benzoate |
| Synonyms / Alt Names | PRL-8-053, Methyl 3-[2-[benzyl(methyl)amino]ethyl]benzoate HCl |
| CAS Number | 51352-87-5 (HCl Salt) / 51352-88-6 (Free Base) |
| Chemical Formula | C18H21NO2 • HCl (C18H22ClNO2) |
| Molecular Weight | 319.83 g/mol (HCl Salt) / 283.37 g/mol (Free Base) |
| IUPAC Name | methyl 3-[2-[benzyl(methyl)amino]ethyl]benzoate;hydrochloride |
| InChIKey | InChIKey=GZSZRLUHYOIQDV-UHFFFAOYSA-N |
| SMILES Code | CN(CCC1=CC(=CC=C1)C(=O)OC)CC2=CC=CC=C2.Cl |
| Physical Appearance | White to Off-White Crystalline Dry-Fill Powder in Solid Capsules |
The biochemical pathways and cellular targets of PRL-8-53 in laboratory research include:
When evaluating published scientific literature and neurochemical monographs for PRL-8-53:
In neurochemical and synaptic signaling research, benchmark compounds operate across distinct molecular targets, receptor families, and enzymatic pathways:
| Compound / Reference | Chemical Class & Structure | Primary Mechanistic Targets | Primary Research Focus |
|---|---|---|---|
| PRL-8-53 (10MG) | Substituted Benzoic Acid Ester (HCl) | Post-synaptic cholinergic facilitation; dopaminergic potentiation; 5-HT modulation | Cholinergic transmission kinetics, dopamine turnover modeling, and synaptosomal assays |
| Noopept | Synthetic Dipeptide Ethyl Ester | AMPA/NMDA modulation; hippocampal NGF & BDNF upregulation | Synaptogenesis, neurotrophin expression, and cellular neuroprotection modeling |
| Phenylpiracetam Hydrazide | Phenylated Pyrrolidone Hydrazide | AMPA positive allosteric modulation & high-affinity choline uptake (HACU) | Rapid membrane diffusion, glutamatergic synaptic plasticity, and cholinergic kinetics |
| Bromantane | Synthetic Adamantane Derivative | Tyrosine Hydroxylase (TH) transcription & GABA facilitation | De novo dopamine biosynthesis, cellular actoprotection, and stress resilience |
Yes, Modern Aminos is a highly trusted vendor for analytical research chemicals and neurochemical standards. Every batch of PRL-8-53 10MG capsules undergoes strict third-party analytical testing (including HPLC and High-Resolution Mass Spectrometry) to confirm minimum 98%+ active chemical purity, verified molecular weight (319.83 g/mol), exact 10MG unit mass fill calibration, and the complete absence of heavy metals or synthetic solvent impurities.
PRL-8-53 is a synthetic substituted benzoic acid ester chemically designated as methyl 3-(2-(benzyl(methyl)amino)ethyl)benzoate hydrochloride. It belongs to the tertiary aminoethyl benzoate chemical family, synthesized as an analytical compound to explore central neurotransmitter dynamics.
PRL-8-53 facilitates central cholinergic transmission by sensitizing post-synaptic responsiveness to acetylcholine. It does not function as an acetylcholinesterase inhibitor, but rather augments downstream signal transduction efficiency in neuronal tissue preparations.
PRL-8-53 potentiates dopamine turnover and post-synaptic signaling without causing non-vesicular release or abrupt transporter reversal, allowing researchers to study physiological dopamine transmission without triggering receptor down-regulation or tachyphylaxis.
Modern Aminos supplies analytical-grade PRL-8-53 in pre-measured dry-fill solid capsules containing 10MG of active compound per capsule, bottled in 60-count configurations to ensure precise gravimetric unit mass control for laboratory benchtop research.
PRL-8-53 is a substituted benzoic acid ester that primarily potentiates post-synaptic cholinergic and dopaminergic signaling. In contrast, Noopept is a dipeptide ester that upregulates neurotrophic factors (NGF and BDNF) and modulates ionotropic glutamate receptors (AMPA/NMDA) in neuronal cell lines.
Modern Aminos utilizes High-Performance Liquid Chromatography (HPLC) to confirm active compound purity exceeding 98% and High-Resolution Mass Spectrometry (HRMS) to verify exact molecular mass (319.83 g/mol) and unit gravimetric fill consistency prior to batch release.
PRL-8-53 capsule bottles should be maintained tightly sealed in a cool, dry environment (15°C to 25°C) protected from direct sunlight, thermal extremes, and atmospheric moisture to preserve solid-phase chemical stability throughout the designated shelf life.
Disclaimer: All compounds and research materials provided by Modern Aminos are strictly for laboratory and research professional use only. They are not approved for human or animal use nor consumption by the Food and Drug Administration (FDA). These products should not be used for any form of in vivo experimentation or for any other non-laboratory purpose. Any violation or indication of human or animal use will result in immediate removal from being able to purchase products in the future. By purchasing these products, you acknowledge that they will be used exclusively within a controlled and qualified research environment.
The products offered by Modern Aminos are intended strictly for laboratory research purposes only and are sold exclusively to qualified professionals, institutions, and entities. These products are not for human consumption, veterinary use, or any other application involving living organisms, including but not limited to diagnostic, therapeutic, or recreational purposes.
By purchasing this product, you confirm that:
Modern Aminos does not claim that this product is approved by the U.S. Food and Drug Administration (FDA) for any purpose. The statements regarding this product have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
The buyer assumes full responsibility for ensuring the safe handling, storage, and use of this product. Modern Aminos is not liable for any damages, direct or indirect, resulting from improper handling, storage, or unauthorized use of this product. Furthermore, Modern Aminos reserves the right to refuse sales to any individual or entity suspected of misusing its products.
If you have questions about the safe and lawful use of this product, consult a qualified professional with expertise in laboratory research. By proceeding with this purchase, you agree to these terms and conditions.
